Objectives: High rates of methicillin-resistant Staphylococcus aureus (MRSA) and fluoroquinolone-resistant Pseudomonas aeruginosa may be related, in part, to the overuse of fluoroquinolones. The objective was to analyse and correlate long-term surveillance data on MRSA and fluoroquinolone-resistant P. aeruginosa rates and antibiotic consumption after implementation of an institution-wide programme to reduce fluoroquinolone use.
Introduction
The increasing prevalence of antimicrobial-resistant organisms is a major public health issue and is of particular concern in hospitals. Staphylococcus aureus and Pseudomonas aeruginosa are two major nosocomial pathogens that both express multidrug resistance. Rates of antimicrobial resistance in hospitals are affected by various factors, including local epidemiology, infection control practices and usage patterns for antibiotics. The use of antibiotic therapy to treat individuals has an ecological impact on all the patients hospitalized in the same facility, and the correlation between the use of antibiotics and the development of antibiotic resistance is widely accepted. 1 -3 Indeed, the relationship between increasing fluoroquinolone (FQ) use and decreasing susceptibility to FQs has been shown in Gramnegative bacteria and S. aureus. 4 -7 Among Gram-negative bacilli, a notable reduction in ciprofloxacin susceptibility, correlated to the increase in use of FQs, was reported with P. aeruginosa. 5,8 -12 Bacterial resistance leads not only to longer and more costly hospital stays, but also to increased morbidity and death rates. 5 Whether resistance is reversible and a reduction in antimicrobial use would result in a parallel reduction in bacterial resistance is still to be determined. Studies addressing the effect of the reduction of antibiotic use on bacterial resistance have reported conflicting results. 13 -16 Few studies have analysed the impact of a specific reduction of FQ consumption on resistance in the community or in hospitalized patients. 15 The long-term impact of FQ use reduction has been rarely addressed. 17 The purpose of this study was to analyse antibiotic consumption in our hospital after implementation of an institution-wide programme to reduce FQ use and correlate it to the incidence of antimicrobial resistance among S. aureus and P. aeruginosa isolates.
Methods

FQ control programme
Saint-Louis hospital is a 600-bed acute care university hospital with great activity in haematology and oncology. A programme aimed at reducing the staff was advised against the empirical use of FQs. These recommendations were provided to all prescribing physicians. (iv) A procedure of individualized therapeutic recommendations was subsequently implemented. This on-going activity consisted of daily counseling by the antimicrobial stewardship team physician on antibiotic prescriptions, prompted by microbiological results (positive blood cultures, isolation of resistant bacteria or any serious infection) and/or initiated by the prescribers.
Study design
We conducted an interrupted times series/quasi-experimental study in which three periods were defined. The first period was the pre- During the three periods we measured FQ and alcohol-based hand-rub (ABHR) solution use and also studied bacterial resistance. The monthly FQ consumption in our hospital was retrieved from the computerized database of pharmacy records. FQs available for oral and intravenous administration were analysed (ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin and norfloxacin). The total antibiotic use rate per year in our institution was also recorded by the central pharmacy during the same period. All antibiotics prescribed for inpatients were collected. FQ use was also studied, on a yearly basis, in the regional Coordinating Centres for Nosocomial Infection Control (CCLIN-Nord) network and compared with our hospital data. CCLIN-Nord is a network whose main missions cover healthcare-associated infections and antimicrobial resistance prevention and control, encompassing 700 healthcare facilities (including our institution) in the north of France. The application we used included all antibacterial drugs marketed in France for systemic use [J01 class of the WHO Anatomical Therapeutic Chemical (ATC) classification] in defined daily doses per 1000 patient-days (DDD/1000 PD).
As the effect of ABHR solution use on methicillin-resistant S. aureus (MRSA) rate has been reported, the monthly ABHR solution use in Saint-Louis hospital was also recorded and expressed in litres (L) per 1000 PD using the data provided by the central pharmacy. 18 To evaluate the impact of the programme on antimicrobial resistance, we chose to study two nosocomial pathogens, i.e. S. aureus and P. aeruginosa. A retrospective observational study on MRSA and FQ-resistant P. aeruginosa isolation rates was carried out from January 2000 through to March 2010. All non-duplicate strains isolated from clinical specimens in patients hospitalized were analysed, including blood, urine, skin and respiratory specimen cultures. Susceptibility tests were performed using national guidelines. Duplicate strains, defined as strains with the same antibiotic susceptibility pattern already counted for the same patient, regardless of the site from which they were isolated, were excluded. The results were given as the proportion (expressed as a percentage) of MRSA among clinical isolates of S. aureus and FQ-resistant P. aeruginosa strains among clinical isolates of P. aeruginosa. Relative changes in resistance rates were calculated as a percentage over all the study period and per month.
Statistical analysis
The effect of the intervention on the use of FQs and bacterial resistance was assessed using segmented regression analyses. 19 For FQ consumption, segmented linear regression was used, while segmented Poisson regression was used for counts of resistant isolates. Models included an intercept (mean value at the beginning of the study) and linear time trends for each study period (before intervention, during intervention and after intervention). Whenever necessary, non-linear polynomial effects were added to the model to improve the fit of observed data. The model formulation was then selected by minimization of Akaike's information criterion (AIC). Study period main effects were also included to avoid constrained models. Seasonal effects were investigated by adding yearly and bi-yearly periodic effects to the models. Once a model was fitted, the model fit was examined by residual versus fitted plots. For segmented linear regression, quantile-to-quantile plots of residuals and the Breusch-Pagan test for heteroskedascticity were also used. For segmented Poisson regression, models with overdispersion were used. Additionally, generalized additive models with splines were also used to investigate non-linear time trends within the study periods. The independence of residuals was investigated using their autocorrelation and partial autocorrelation functions that showed no significant autocorrelation, thus justifying the independence assumption. P values of ,0.05 were considered to be statistically significant for all tests. Analyses were performed using R statistical software version 2.10.1.
Results
Impact of the programme on antibiotic use
During the pre-intervention period, a constant and significant overall increase in FQ (essentially ofloxacin and ciprofloxacin) consumption was observed (on average, +0.37 DDD/1000 PD/month; P ¼ 0.006) (Figure 1 A statistically significant change in slope of yearly consumption of antibiotics other than FQs was also found during the postintervention period as compared with the pre-intervention period (P ¼ 0.001) (data not shown). This decrease was significantly lower than that of FQ use, with an average decrease by 6.0%/year for non-FQ antibiotics as compared with 10.1% for FQs (P,0.0001).
The study of yearly FQ use in CCLIN-Nord hospitals showed a much lower FQ use rate compared with our hospital, but that did not change during the study period (average non-significant increase 0.4 DDD/1000 PD/year, 95% CI 21.4 to +2.1, P ¼ 0.62) (Figure 2 ).
ABHR solution use
The monthly ABHR solution consumption from January 2000 to January 2010 is reported in Figure 3 
Changes in antibiotic resistance
Overall, 2239 specimens of P. aeruginosa and 3760 specimens of S. aureus were isolated during the study period and tested for FQ and methicillin resistance, respectively. The number of monthly analysed isolates of P. aeruginosa increased from a mean of 18.5 (SD 5.4) at the beginning of the study period to 28.2 (SD 8.0) at the end, while the monthly number of S. aureus specimens remained stable-on average, 37.6 (SD 10.2) throughout the study period.
During the pre-intervention period, the rate of FQ-resistant P. aeruginosa isolates did not vary linearly with time (P¼ 0.008 in the Poisson model) (Figure 4) . The mean observed resistance rate was 42% (SD 13) in the first 6 months of 2002 and 42% (SD 9) in the last 6 months before implementation of the intervention. During the intervention period, the FQ-resistant P. aeruginosa rate did not vary significantly (P¼ 0.60). In the post-intervention period; however, the time trend for FQ J a n 2 0 0 0 J a n 2 0 0 1 J a n 2 0 0 2 J a n 2 0 0 3 J a n 2 0 0 4 J a n 2 0 0 5 J a n 2 0 0 6 J a n 2 0 0 7 J a n 2 0 0 8 J a n 2 0 0 9 J a n 2 J a n 2 0 0 0 J a n 2 0 0 1 J a n 2 0 0 2 J a n 2 0 0 3 J a n 2 0 0 4 J a n 2 0 0 5 J a n 2 0 0 6 J a n 2 0 0 7 J a n 2 0 0 8 J a n 2 0 0 9 J a n 2 0 1 0 FQ consumption (DDD/1000 PD) Lafaurie et al.
resistance of P. aeruginosa was significantly modified as compared with pre-intervention (P ¼ 0.011). The FQ resistance rate of P. aeruginosa continuously decreased to 26%, with a constant relative change rate of 213%/year (95% CI 219 to 25, P ¼ 0.001).
The rates of S. aureus isolates resistant to methicillin are depicted in Figure 5 . On average, 26% (SD 7) of isolates were resistant to methicillin the first 6 months of the pre-intervention period, 26% (SD 9) during the last 6 months of the preintervention period, and 14% (SD 3) during the last 6 months of the post-intervention period ( Figure 5) . The model best fitting the data showed a significantly lower rate of resistance in the post-intervention period, with a decrease during the intervention period from a mean resistance rate of 27% to 21% (P,0.0001), with no further evidence of variation within each study period. In particular, the rate of methicillin resistance during the pre-intervention period remained stable (relative change rate per year 20.7%, 95% CI 29 to 9), whereas a nonsignificant decrease was observed in the post-intervention period (relative change rate per year 27%, 95% CI 215 to 2).
Changes in FQ-resistant P. aeruginosa and MRSA rates were confirmed when adjusting the analysis on the consumption of ABHR solution.
Discussion
In this study we demonstrated the sustained efficacy of a programme aimed at decreasing the use of FQs; their use decreased significantly over almost 4 years following the implementation of this intervention. The durability of the effect of an intervention on physician antibiotic-prescribing behaviour has been evaluated in a few studies. 20 -22 The long-lasting effect of our programme on FQ use may be due, in part, to the continuous educational outreach visits by the antimicrobial stewardship infectious diseasestrained physician to providers after the intervention period. Of note, no formulary restriction was used, although this would contribute significant reductions in antimicrobial use. 23 When analysing data from institutions in the CCLIN-Nord network as a control, we observed that FQ use during the pre-intervention period at Saint-Louis hospital was much higher. This may be explained by the major clinical activities in HIV, haematology and oncology in our hospital. However, we showed that, unlike Saint-Louis hospital, FQ use did not decrease in other hospitals. This reinforced the assertion that FQ use decreased in our hospital was a direct result of the programme we implemented.
We also assessed whether the reduction in FQ use translated into a decrease in antimicrobial resistance. We observed a significant decrease in FQ-resistant P. aeruginosa and MRSA rates. We should be cautious, however, before concluding that there is a causal association with the decrease in FQ use, particularly if we look at three factors. First, a decrease in the MRSA rate was also observed in other French hospitals of the Assistance Publique -Hô pitaux de Paris, hospitals that are closed to Saint-Louis hospital in terms of location, structure and recruitment.
J a n 2 0 0 2 J a n 2 0 0 3 J a n 2 0 0 4 J a n 2 0 0 5 J a n 2 0 0 6 J a n 2 0 0 7 J a n 2 0 0 8 J a n 2 0 0 9 J a n 2 0 J a n 2 0 0 2 J a n 2 0 0 3 J a n 2 0 0 4 J a n 2 0 0 5 J a n 2 0 0 6 J a n 2 0 0 7 J a n 2 0 0 8 J a n 2 0 0 9 J a n 2 0 1 0 MRSA rate (%) Fluoroquinolone use decrease and MRSA and P. aeruginosa resistance reduction contributed to the decrease in antibiotic resistance rates. However, the MRSA rate was not significantly modified during the pre-intervention period, although ABHR solutions use increased up to 20 L/1000 PD and there is no demonstrated benefit of ABHR solution use on P. aeruginosa FQ resistance. Regression analyses used in our study allow the estimation of associations between the intervention and microbial resistance and FQ use. 19 The strength of our analysis is that we used data from multiple pre-and post-intervention time intervals (i.e. months) to estimate the slope. The use of at least 10 observations per model parameter is usually suggested to avoid overfitting. A number of studies looking at the relationship between antibiotic consumption and microbial resistance used one point of measurement per year; that is too few to allow a time series analysis. 24 Few intervention studies have attempted to decrease antimicrobial resistance by active antibiotics policies, with most studying MRSA rates only. 17,25 -29 A Cochrane review, published in 2005, did not present strong evidence to support MRSA control by antibiotic stewardship interventions. 16 As for P. aeruginosa, studies looking at the effects of a decrease in FQ use on FQ resistance rates are scarce and provide little evidence. 30, 31 However, our study has a number of limitations. The design was not a randomized controlled trial. Consequently, statistical association between a decrease in FQ use and a favourable impact on resistant pathogens could not been formally demonstrated. Furthermore, rates of antimicrobial resistance and the isolation of resistant bacteria in hospitals are affected by various factors, including infection control practices, usage patterns for antibiotics, local epidemiology and the medical and surgical procedures performed at the hospital. Our study was not designed to look at all these aspects. However, we did ascertain that neither outbreaks of MRSA or P. aeruginosa nor infection control policy changes occurred during the study time frame. We could also not discriminate between cross-transmission and antimicrobial selection pressure in the levels of bacterial resistance observed.
Thus, we demonstrated the long-lasting impact of a FQ control programme on FQ use by combining several types of action maintained over time. If our study could not demonstrate that decreasing FQ use led to reduced FQ-resistant P. aeruginosa and MRSA rates, it suggests nevertheless the positive impact of FQ use reduction on antimicrobial resistance.
